India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Lars Fruergaard Jørgensen is a CEO who didn't want to be CEO but under his tenure Novo Nordisk, which makes Ozempic, has ...

A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the ...

After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...

Lars Fruergaard Jørgensen might not be a household name, but his company’s drug Ozempic is. And its success has thrust him — ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Infinitus is trying to catch the attention of Big Pharma with a billboard-based campaign rolling out in New Jersey, spelling out a future where humans and AI work together.

If successful, Mankind’s drug would be the first oral small-molecule alternative, offering a pill-based treatment.